Biotechnology companies are emerging as the most active segment of the U.S. IPO market during a quieter stretch for new listings. Over the past three months, 11 biotech and drug-development companies have priced Nasdaq IPOs, raising about $2.5 billion before over-allotments and signaling a potential second wave of healthcare offerings.
Highlights
- Biotech and drug-development IPOs lead the U.S. listings market with 11 Nasdaq deals raising approximately $2.5 billion since early July.
- Newly listed biotechs like Vogenx and Scribe Therapeutics posted intraday highs of nearly 200% and 84% above their offering prices, while overall sector trading remains volatile.
- Non-S&P 500 healthcare stocks gained an average of 71.2% over the past 12 months, with recent IPO bursts—such as Electra Therapeutics ($350 million) and ADARx ($446 million)—signaling continued sector momentum.
Recent biotech listings and early trading performance
As reported by Weiss Ratings, biotech and drug-development groups account for the largest cluster of operating-company IPOs in its database since early July, with 11 deals priced on Nasdaq over the last three months. The sector's fundraising total reaches about $2.5 billion before over-allotments, underscoring how healthcare is driving issuance even as the broader IPO calendar remains uneven.Early post-listing trading shows a wide range of outcomes, but several names post sharp gains from their second-day opening prices to subsequent intraday highs. Vogenx rises from its listing level to a peak of $38.41 on Sept. 18, nearly tripling after pricing at $13, while gene-editing company Scribe Therapeutics climbs 84% to a high of $39.60 on Aug. 20. Other newly public biotechs, including Braveheart Bio, Electra and ADARx, peak 8%, 4% and 15% above their second-day opens, while Retension Pharma and TRexBio have only recently priced and remain under watch.
Performance also reflects the volatility typical of clinical-stage biotechnology stocks, where valuations often depend on trial milestones that have not yet arrived. Of the companies highlighted, only Vogenx, Scribe and BlossomHill remain above their reference levels at the time of writing, showing that sharp early gains do not necessarily translate into sustained trading strength.
Healthcare momentum and a possible second issuance wave
Broader market data cited in the analysis suggests the IPO activity is aligning with stronger healthcare stock performance beyond the largest index names. Over the 12 months through Sept. 25, healthcare companies outside the S&P 500 gain an average of 71.2%, ahead of every other sector measured and above the S&P 500's 18.2% rise over the same period.That outperformance appears to extend beyond a handful of standout stocks. The typical non-S&P healthcare company gains about 24.5%, roughly two-thirds of the group advances, and the segment still posts a 64.0% gain even after removing the 10 best performers, indicating breadth in smaller-cap healthcare returns.
The recent IPO burst also appears concentrated in waves rather than a steady flow. Seven of the 11 biotech IPOs price between July 24 and Aug. 12, followed by a mid-August lull, but activity picks up again with Electra Therapeutics raising $350 million at $15 a share on Sept. 18 and ADARx Pharmaceuticals raising $446 million at $17 a share a week later, the largest deal among the recent group. TRexBio then raises $117 million and Retension adds $45 million, while at least four more healthcare companies file to go public between Sept. 18 and 25. Iambic Therapeutics and City Therapeutics are also scheduled for later this week, pointing to a potential continuation of biotech-led issuance.
SEBI’s proposed overhaul of India’s SME IPO rules could tighten eligibility while still preserving a route to market for smaller issuers backed by institutional demand. Our earlier article explained how shifting exchange rules and trading trends can influence capital formation and listing activity, highlighting how regulatory frameworks and market structure changes affect who can go public and on what terms.